CellCarta Acquires Commercial Rights to Immuno‑MRM Assays from Precision Assays
May 19, 2022
CellCarta acquired the commercial rights to antibody panels and next‑generation immuno‑MRM assays from Fred Hutch spin‑off Precision Assays, expanding its off‑the‑shelf multiplex proteomics offerings for immuno‑oncology. The deal brings validated CPTAC‑characterized assays into CellCarta's global precision‑medicine service platform, enabling faster deployment in translational and clinical studies.
- Buyers
- CellCarta
- Targets
- Precision Assays
- Sellers
- Precision Assays
- Industry
- Healthcare Services
- Location
- Washington, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
McKesson to Acquire Precision Medicine Group, LLC for Approximately $2.25 Billion
August 25, 2026
Healthcare Services
McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. After completion, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment, subject to customary regulatory closing conditions.
-
BioIVT Acquires PrecisionMed
July 18, 2023
Healthcare Services
BioIVT, a global biospecimen solutions provider, has acquired PrecisionMed, LLC, a Carlsbad-based supplier of high-quality human biospecimens and owner of a large longitudinal cerebrospinal fluid (CSF) repository. The acquisition expands BioIVT's supply network, inventory and capacity for CSF and liquid biopsy products while PrecisionMed will continue to operate from its existing headquarters and collection sites.
-
CellCarta Acquires Biogazelle
December 14, 2021
Biotechnology
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
CellCarta Acquires Reveal Biosciences
May 11, 2021
Healthcare Services
CellCarta has acquired Reveal Biosciences, a San Diego–based computational pathology company specializing in AI-driven quantitative pathology and digital image analysis. The acquisition adds Reveal's imageDx platform and AI-based pathology capabilities to CellCarta's histological biomarker and precision medicine services, broadening its AI-enabled multi-omic analysis offerings for biopharmaceutical research and clinical trials.
-
Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Medical Devices
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.